Taiwanese biotech developing biomedical/regenerative-medicine products; specific pipeline and commercial products unconfirmed.
Taiwanese biotech developing biomedical/regenerative-medicine products; specific pipeline and commercial products unconfirmed.
Moat: none
Headquarters: Taiwan
Size PELL Bio-Med Technology (6949.TW) is a Taiwan Health Care company (Biotechnology) with a market value of $1.62B, the 192nd largest of 648 Taiwan companies the cockpit tracks. Shares closed at NT$45.05 on 18 Nov 2026.
Performance Over six months the shares gained 28.4%, against -11.9% for the median peer and -3.4% for the Taiwan market (cap-weighted) — 5th highest of 20 in its peer set.
Growth Revenue grew 7.8% over the last twelve months (peer median +24.9%); the operating margin is -1,463.2% (peer median 7.6%).
Valuation It trades at 1,650.2× enterprise value to sales against a peer median of 11.7× (most expensive of 18).
Capital Return on invested capital runs 23.9 points below its cost of capital (8.6% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | NT$32.3M | NT$31.4M | NT$19.6M | NT$18.0M | NT$17.2M |
| Revenue growth | — | +60% | +9% | +5% | — |
| Gross profit | -NT$5.62M | -NT$51.5M | -NT$59.2M | -NT$71.8M | -NT$42.3M |
| EBITDA | n/a | -NT$420M | -NT$367M | -NT$366M | -NT$205M |
| Net income | -NT$420M | -NT$424M | -NT$389M | -NT$399M | -NT$230M |
| Free cash flow | n/a | -NT$508M | -NT$524M | -NT$196M | -NT$162M |
| Capital expenditure | n/a | NT$247M | NT$285M | NT$16.5M | NT$8.49M |
| Total debt | n/a | NT$237M | NT$365M | NT$173M | NT$203M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 6949.TW | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +15.8% | -8.0% | highest of 21 |
| 6-month return | +28.4% | -11.9% | 5th highest of 20 |
| Distance from 52-week high | -45.0% | -42.4% | 9th lowest of 21 |
| Revenue growth (TTM) | +7.8% | +24.9% | 6th lowest of 19 |
| Operating margin | -1,463.2% | 7.6% | 3rd lowest of 19 |
| EV / Sales | 1,650.2× | 11.7× | most expensive of 18 |
| ROIC minus cost of capital | -23.9 pp | -4.0 pp | 5th lowest of 15 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| PELL Bio-Med Technology 6949.TW | Taiwan | $1.62B | +28% | +8% | -1,463% | 1,650.2× | n/a | n/a |
| Hitgen 688222.SS | China | $1.62B | -3% | +42% | 27% | 14.4× | 33.2% | +16.8% |
| Alvotech ALVO | United States | $1.62B | +38% | -14% | 12% | 6.4× | n/a | n/a |
| ANI Pharmaceuticals ANIP | United States | $1.62B | -13% | +26% | 15% | 1.7× | -7.6% | +33.5% |
| PolyPeptide PPGN.SW | Switzerland | $1.61B | +7% | +22% | 7% | 3.4× | n/a | n/a |
| Zhejiang Hengtong 600226.SS | China | $1.64B | -31% | +71% | 0% | 4.2× | n/a | n/a |
| Vir Biotechnology VIR | United States | $1.57B | +3% | +1,696% | -70% | 4.0× | n/a | n/a |
| Hugel 145020.KS | South Korea | $1.69B | -30% | +17% | 38% | 3.6× | -12.1% | +15.0% |
| Nurix Therapeutics NRIX | United States | $1.54B | -14% | +739% | 41% | 0.8× | n/a | n/a |
| Precigen PGEN | United States | $1.53B | 0% | +2,388% | 21% | 10.1× | n/a | n/a |
| Kailera Therapeutics KLRA | United States | $1.53B | -41% | n/a | n/a | n/a | n/a | n/a |
| Korsana Biosciences KRSA | United States | $1.52B | +54% | -64% | -5,277% | 1,058.7× | n/a | n/a |
| Chengdu Olymvax Biopharmaceuticals 688319.SS | China | $1.51B | -37% | +12% | 8% | 13.1× | n/a | n/a |
| Stoke Therapeutics STOK | United States | $1.75B | -12% | -86% | -913% | 50.6× | n/a | n/a |
| TLC BioSciences 7924.TWO | Taiwan | $1.50B | n/a | n/a | n/a | n/a | n/a | n/a |
| Recursion Pharmaceuticals RXRX | United States | $1.76B | -5% | +56% | -725% | 18.8× | n/a | n/a |
| Peptron 087010.KS | South Korea | $1.49B | -68% | -13% | -488% | 359.6× | n/a | n/a |
| Mesoblast MSB.AX | Australia | $1.49B | -17% | +556% | -43% | 12.8× | n/a | n/a |
| GemPharmatech 688046.SS | China | $1.78B | +39% | +25% | 22% | 11.7× | 33.0% | +24.8% |
| Fujian Haixi Pharmaceuticals 2637.HK | Hong Kong | $1.47B | -32% | +25% | 33% | n/a | n/a | n/a |
| Zenas BioPharma ZBIO | United States | $1.79B | +35% | -27% | -2,748% | 146.1× | n/a | n/a |